Login
Navigate Fool.com
Will ARQL beat
the market?

ArQule, Inc.

NASDAQ: ARQL

Community Rating: 3 Stars: Appealing

1.66 -0.02 (-1.19%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.69
Previous Close $1.68
Daily Range $1.65 - $1.71
52-Week Range $1.62 - $3.10
Market Cap $104.4M
P/E Ratio -4.31
Dividend (Yield) $0.00 (0.0%)
Volume 188,790
Average Daily Volume 354,426
Current FY EPS -$0.49

How do you think ARQL
will perform against the market?

Top ARQL Bull/Bear Pitches

 

NetscribeHealthC (< 20)
Submitted March 12, 2007

ArQule is developing a portfolio of proprietary small molecule drugs to treat cancer. The company’s technology platform includes the Activated Checkpoint Therapy (ACT) program, which seeks to harness … More

0 Replies Reply Report this Post
 

pajeth (3.68)
Submitted February 19, 2007

Carefully watching this stock, hoping for some positive news.

1 Replies Reply Report this Post

News & Commentary

This Week in Biotech: Clinical Trials and Tribulations

The J.P. Morgan Healthcare Conference led to the release of five important clinical updates this week.

Healthcare Stocks Declining; ArQule Jumps After Data Committee Signs Off On Continued Study of Cance

Healthcare Stocks Declining; ArQule Jumps After Data Committee Signs Off On Continued Study of Cancer Medication

Sector Update: Healthcare

Why ArQule Inc. Shares Surged in After-Hours Trading

ArQule shares surge 26% after updating clinical trial data for key cancer drug tivantinib.

Four Unusual Stock Winners on a Down Friday

5 of Last Week's Biggest Losers

These five stocks posted double-digit percentage declines last week.

Healthcare Stocks Holding Small Gains; ArQule Slumps After Committee Recommends Smaller Trial Dosage

Healthcare Stocks Holding Small Gains; ArQule Slumps After Committee Recommends Smaller Trial Dosages

Sector Update: Healthcare

ArQule Reports Second Quarter 2013 Financial Results

ArQule to Report Second Quarter 2013 Financial Results on July 30, 2013

See More ARQL News...

Sector

Healthcare

Industry

Drugs

ArQule, Inc. (ARQL) Description

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. Website: http://www.arqule.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks